TLR3 (52) and TLR9 (56) have been associated with cell proliferation in head and neck cancer, and Ruan et al. (58) suggested that the use of anti-TLR9 agents may reduce tumor cell proliferation in OSCC as well as reducing metastatic potential. The gene discussed is TLR3; the disease is head and neck cancer.